← 返回

Cancer and heart failure: prevalence, incidence, and prognosis in Scotland.

Cancer and heart failure: prevalence, incidence, and prognosis in Scotland.

期刊: Eur Heart J 日期: 2026-01-01 PMID: 42068332 DOI: 10.1093/eurheartj/ehag120 浏览: 45
作者: Iaconelli Antonio, Morsy Moustafa I, Friday Jocelyn M, Pellicori Pierpaolo, Elyan Benjamin M P, Lang Ninian N, Pell Jill P, Lewsey Jim, Mackay Daniel F, Dundas Ruth, Tran Tran Q B, Brown Denise, Ho Frederick K, Hastie Claire E, Fleming Michael, Geue Claudia E, Stevenson Alan, du Toit Clea, Padmanabhan Sandosh, Maffia Pasquale, Sensini Luca, Feccia Maria Vittoria, Pecorini Giovanni, Anker Stefan D, Anker Markus S, Crea Filippo, Cleland John G F
Antonio, I., I, M.M., M, F.J., Pierpaolo, P., P, E.B.M., N, L.N., P, P.J., Jim, L., F, M.D., Ruth, D., B, T.T.Q., Denise, B., K, H.F., E, H.C., Michael, F., E, G.C., Alan, S., Clea, d.T., Sandosh, P., . . . F, C.J.G. (2026). Cancer and heart failure: prevalence, incidence, and prognosis in Scotland.. Eur Heart J. https://doi.org/10.1093/eurheartj/ehag120
Antonio I, I MM, M FJ, Pierpaolo P, P EBM, N LN, et al. Cancer and heart failure: prevalence, incidence, and prognosis in Scotland.. Eur Heart J. 2026; doi: 10.1093/eurheartj/ehag120
Antonio I, I MM, M FJ, et al. Cancer and heart failure: prevalence, incidence, and prognosis in Scotland.[J]. Eur Heart J. 2026. DOI: 10.1093/eurheartj/ehag120.
@article{antonio2026,
  author = {Iaconelli Antonio and Morsy Moustafa I and Friday Jocelyn M and Pellicori Pierpaolo and Elyan Benjamin M P and Lang Ninian N and Pell Jill P and Lewsey Jim and Mackay Daniel F and Dundas Ruth and Tran Tran Q B and Brown Denise and Ho Frederick K and Hastie Claire E and Fleming Michael and Geue Claudia E and Stevenson Alan and du Toit Clea and Padmanabhan Sandosh and Maffia Pasquale and Sensini Luca and Feccia Maria Vittoria and Pecorini Giovanni and Anker Stefan D and Anker Markus S and Crea Filippo and Cleland John G F},
  title = {Cancer and heart failure: prevalence, incidence, and prognosis in Scotland.},
  journal = {Eur Heart J},
  year = {2026},
  doi = {10.1093/eurheartj/ehag120},
  note = {PMID: 42068332},
}
TY  - JOUR
AU  - Iaconelli Antonio
AU  - Morsy Moustafa I
AU  - Friday Jocelyn M
AU  - Pellicori Pierpaolo
AU  - Elyan Benjamin M P
AU  - Lang Ninian N
AU  - Pell Jill P
AU  - Lewsey Jim
AU  - Mackay Daniel F
AU  - Dundas Ruth
AU  - Tran Tran Q B
AU  - Brown Denise
AU  - Ho Frederick K
AU  - Hastie Claire E
AU  - Fleming Michael
AU  - Geue Claudia E
AU  - Stevenson Alan
AU  - du Toit Clea
AU  - Padmanabhan Sandosh
AU  - Maffia Pasquale
AU  - Sensini Luca
AU  - Feccia Maria Vittoria
AU  - Pecorini Giovanni
AU  - Anker Stefan D
AU  - Anker Markus S
AU  - Crea Filippo
AU  - Cleland John G F
TI  - Cancer and heart failure: prevalence, incidence, and prognosis in Scotland.
T2  - Eur Heart J
PY  - 2026
DO  - 10.1093/eurheartj/ehag120
AN  - PMID:42068332
ER  - 

摘要

Many patients with cancer develop heart failure (HF), and many patients with HF develop cancer. Inter-relationships between their natural histories are rarely reported. Health records were obtained for a Scottish region. People aged >50 years were classified by the presence or absence of HF, loop diuretics (a pharmacological marker of congestion), and cancer. Incident cancer, mortality, and cause of death were recorded. Of 317 178 people aged >50 years, 11 268 (3.6%) had HF of whom 6276 were prescribed loop diuretics; a further 19 044 (6.0%) received loop diuretics. Thus, 30 312 (9.6%) people met an expanded definition of heart failure (HFexp). Annual cancer incidence was slightly higher for those with HFexp (incidence rate ratio 1.10; P < .001), varying amongst cancer types. For people with neither cancer nor HFexp, mortality was <3% annually; most deaths were cardiovascular. For those with cancer but not HFexp, annual mortality was 6.3% for women and 9.0% for men; most died of cancer. For those with HFexp but not cancer, annual mortality ranged from 6.6% to 18.4% depending on sex and HFexp criteria applied; most deaths were cardiovascular. For those with both cancer and HFexp, annual mortality ranged from 14.5% to 28.4%; cardiovascular and cancer mortality rates were similar. Few patients died at home (∼20%). Patients with HFexp have a slightly higher risk of cancer overall, but this may vary according to cancer type. Patients with both cancer and HFexp have a poor prognosis with a similar proportion of deaths attributed to cancer and cardiovascular disease.

AI 智能解读

相关文献

返回分类: 心衰 查看原文 (DOI)
已选择 0 篇文献